Novartis says novel antimalarial succeeded in late-stage trial
Source: SeekingAlpha
2025-11-13 09:14:25 ET
More on Novartis
- Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
- Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies - Slideshow
- Novartis AG (NVS) Q3 2025 Earnings Call Transcript
- Novartis launches new manufacturing facility in California
- Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
Read the full article on Seeking Alpha
For further details see:
Novartis says novel antimalarial succeeded in late-stage trial
Novartis AG Registered Shares
NASDAQ: NVSEF
NVSEF Trading
-0.98% G/L:
$145.805 Last:
1,044,589 Volume:
$145.805 Open:
NVSEF Latest News
May 07, 2026 09:00:00 am
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
April 30, 2026 07:00:00 am
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
NVSEF Stock Data
$299,675,221,187
2,118,043,712
N/A
1352
N/A
Pharmaceuticals
Healthcare
CH
Basel
